DRPevader: Ex vivo-diagnosis and prognosis of early diabetic retinopathy
A novel ex vivo method for immediate early diagnosis and prognosis of proliferative diabetic retinopathy (DRP) is provided with DRPevader.
DRPevader is based on the analysis of expression and activity of very few genes which can simply be determined using whole blood or a blood component. Therefore, DRPevader is the diagnostic link between the alteration of leukocyte gene expression, the activity of specific serum-markers, and proliferative DRP.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 0
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Economies take off with new airports
A global study by an SUTD researcher in collaboration with scientists from Japan explores the economic benefits of airport investment in emerging economies using nighttime satellite imagery. Be it for…
CAR T–cell immunotherapy targets
Pan-cancer analysis uncovers a new class of promising CAR T–cell immunotherapy targets. Scientists at St. Jude Children’s Research Hospital found 156 potential CAR targets across the brain and solid tumors,…
Stony coral tissue loss disease
… is shifting the ecological balance of Caribbean reefs. The outbreak of a deadly disease called stony coral tissue loss disease is destroying susceptible species of coral in the Caribbean…
